Get the Stockscreener App
12.58
0.64%
0.08
Astria Therapeutics Inc stock is traded at $12.58, with a volume of 3.15M.
It is up +0.64% in the last 24 hours and down -2.48% over the past month.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
See More
Previous Close:
$12.50
Open:
$12.48
24h Volume:
3.15M
Relative Volume:
2.58
Market Cap:
$718.13M
Revenue:
-
Net Income/Loss:
$-72.89M
P/E Ratio:
-5.1983
EPS:
-2.42
Net Cash Flow:
$-68.47M
1W Performance:
+0.88%
1M Performance:
-2.48%
6M Performance:
+88.32%
1Y Performance:
+66.62%
1-Day Range:
$12.45
$12.59
1-Week Range:
$12.24
$12.59
52-Week Range:
$3.555
$13.29
Astria Therapeutics Inc Stock (ATXS) Company Profile
Name
Astria Therapeutics Inc
Sector
Industry
Phone
617-349-1971
Address
22 BOSTON WHARF ROAD, BOSTON
Compare ATXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
12.58 | 718.13M | 0 | -72.89M | -68.47M | -2.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.63 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.34 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.84 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-12-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-17-25 | Reiterated | H.C. Wainwright | Buy |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-31-25 | Initiated | JMP Securities | Mkt Outperform |
| Jul-29-24 | Initiated | TD Cowen | Buy |
| Mar-28-23 | Initiated | Evercore ISI | Outperform |
View All
Astria Therapeutics Inc Stock (ATXS) Latest News
BioCryst Completes Acquisition of Astria Therapeutics (ATXS) - GuruFocus
BioCryst completes $700 million acquisition of Astria Therapeutics - Investing.com
New HAE shot every 3–6 months? BioCryst’s $700M bet on Astria - Stock Titan
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Astria Stockholders Vote to Approve Acquisition by BioCryst - citybiz
Astria Therapeutics (ATXS) Stockholders Approve BioCryst Merger - GuruFocus
Hereditary Angioedema Market Poised for Strong Growth, Valued at ~USD 3 Billion in 2023 and Set to Expand Through 2034: DelveInsight - Barchart.com
Hedge Fund Bets: Is Astria Therapeutics Inc trading at a discount2025 Momentum Check & Free High Return Stock Watch Alerts - baoquankhu1.vn
Astria Therapeutics (NASDAQ:ATXS) Share Price Crosses Below Fifty Day Moving AverageHere's What Happened - MarketBeat
Why (ATXS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
BioCryst Pharmaceuticals Touts ORLADEYO Momentum, Astria Deal and 2026 Outlook at JPM Conference - Yahoo Finance
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® - GlobeNewswire
BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range - Yahoo Finance
Why Astria Therapeutics Inc. stock could outperform in 20252025 Major Catalysts & Free Long-Term Investment Growth Plans - ulpravda.ru
Astria Therapeutics to Present at Upcoming 2025 US Hereditary Angioedema Association National Summit - sharewise.com
Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc.ATXS - PR Newswire
Growth Recap: Is Astria Therapeutics Inc stock in correction or buying zone2025 Trade Ideas & Consistent Profit Focused Trading Strategies - Bộ Nội Vụ
Understanding Momentum Shifts in (ATXS) - Stock Traders Daily
Astria Therapeutics’ STAR-0310 Study: A Promising Step Forward - MSN
JMP Securities Downgrades Astria Therapeutics (ATXS) - MSN
Patterns Watch: Is Astria Therapeutics Inc stock gaining market shareMarket Performance Summary & Capital Efficiency Focused Strategies - moha.gov.vn
Astria faces shareholder lawsuits over planned BioCryst merger - MSN
Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Recommendation of “Hold” by Brokerages - Defense World
Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Astria Therapeutics Advances Phase 3 Trial for Hereditary Angioedema Treatment - MSN
(ATXS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Astria Therapeutics IncComplaints filed against Astria in New York Supreme CourtSEC filing - marketscreener.com
Astria Faces Shareholder Lawsuits Over Planned BioCryst Merger - TipRanks
Astria Therapeutics Merger with BioCryst Pharmaceuticals - TradingView — Track All Markets
Halper Sadeh LLC Encourages ATXS, GDOT, UBFO Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-ATXS, MBCN, FMNB, and SEMR - The Malaysian Reserve
Why Astria Therapeutics Inc. stock appeals to dividend seekersJuly 2025 Reactions & Accurate Entry/Exit Alerts - DonanımHaber
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--ATXS, MBCN, FMNB, and SEMR - Sahm
Astria Therapeutics Earnings Notes - Trefis
Astria Therapeutics (ATXS) price target decreased by 17.94% to 21.62 - MSN
Technical Reactions to ATXS Trends in Macro Strategies - Stock Traders Daily
FDA approves BioCryst's oral pellet version of swelling disorder drug for children - Reuters
BioCryst Pharmaceuticals announces board chair transition following retirement notice By Investing.com - Investing.com UK
BioCryst Pharmaceuticals announces board chair transition following retirement notice - Investing.com
Astria Therapeutics, Inc. $ATXS Shares Acquired by JPMorgan Chase & Co. - MarketBeat
Panagora Asset Management Inc. Purchases New Holdings in Astria Therapeutics, Inc. $ATXS - MarketBeat
Affinity Asset Advisors LLC Purchases Shares of 300,000 Astria Therapeutics, Inc. $ATXS - MarketBeat
Will Astria Therapeutics Inc. stock gain from government policies2025 Market Overview & Verified Swing Trading Watchlists - Newser
Astria Therapeutics (NASDAQ:ATXS) Sees Large Volume IncreaseWhat's Next? - MarketBeat
Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Average Rating of "Hold" from Analysts - MarketBeat
BioCryst’s Ongoing Boost: Buy or Watch? - StocksToTrade
Astria Therapeutics (NASDAQ:ATXS) Sets New 1-Year HighWhat's Next? - MarketBeat
Astria Therapeutics (ATXS) Acquisition Moves Forward with Antitr - GuruFocus
BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition - The Manila Times
BioCryst Pharmaceuticals Announces Early Termination of HSR Waiting Period for Astria Therapeutics Acquisition - Quiver Quantitative
BioCryst receives antitrust clearance for Astria acquisition - Investing.com
Astria Therapeutics Inc Stock (ATXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.38%
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):